Trial Profile
Open-Label Pharmacokinetic Trial of Aldesleukin (rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects with Metastatic Renal Cell Carcinoma or Metastatic Melanoma with Immunologic Correlative Studies.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary)
- Indications Malignant melanoma; Renal cell carcinoma
- Focus Pharmacokinetics
- Sponsors Novartis; Novartis Pharmaceuticals Corporation
- 27 Apr 2012 Company (Novartis Pharmaceuticals Corporation) added in associations field as reported by ClinicalTrials.gov.
- 05 Apr 2011 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 05 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.